Assembly is developing live biotherapeutics for indications that include IBD (ulcerative colitis and Crohn's disease), IBS, immuno-oncology, NASH and metabolic diseases. The public offering will be for 4 million shares at $36/share.
In a small study of 18 children and teenagers with autism, the scientists gave kids fecal transplants from healthy donors over eight weeks. The real surprise was that the kids’ autism symptoms continued to lessen two years after the therapy ended.
The two companies will provide a combined offering from sample collection, ambient temperature stabilization for transport and logistics for all types of microbiome samples and formats, as well as the purification of high quality, inhibitor-free nucleic acids from these samples...
To read the full article, please subscribe to our microbiome database, and you'll receive the rest of the report via email, as well as access to future reports.